SEARCH RESULTS
Report Cards
To improve the implementation of individualized treatments for men with prostate cancer through a better understanding of the protein alterations that occur in tumors.
To provide innovative seed funding to research projects that will generate preliminary data in the prostate cancer field that could then be used to attract a more substantial research grant from another agency.
Discovery of genes which increase the risk of breast cancer in Men. All men may benefit from an improved understanding of male breast cancer diagnosis.
To design, implement and complete hypothesis-driven phase I and phase II trials in prostate cancer, translating scientific discoveries to improved standards of care.
To make discoveries which will improve the length and quality of life of men with prostate cancer, especially prostate cancer which cannot be cured by surgery or radiation therapy.
To make discoveries which will improve the length and quality of life of men with prostate cancer, especially prostate cancer which cannot be cured by surgery or radiation therapy.
To establish Centres of Excellence where scientists and clinicians with different areas of expertise can collaborate to address the big questions in prostate cancer research. Long term and large scale support will ensure that these centres are well placed to deliver breakthrough discoveries and to provide a world-class training ground for the scientists of the future.
To fund research that takes early stage basic discoveries, that we and/or others have previously funded, a step closer to making tangible improvements for men affected by prostate cancer.
These discoveries will revolutionise the treatment and life of men with prostate cancer by finding new ways to prevent cancer growth in bones and prolong the lives of men living with advanced prostate cancer.
These discoveries will revolutionise the treatment of advanced prostate cancer by investigating the adaptive response of prostate cancer cells and tumours to androgen targeted therapies (ATTs) and strategically developing drugs to be used in combination or in sequence with ATT in order to improve and prolong the lives of men living with advanced prostate cancer.
Move discoveries from Movember-funded GAP1 prostate cancer biomarker projects closer to clinical use.